Found 113 matching trials
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NAThis study is looking at outcomes in people with advanced cancers who have ...
Location
Peter MacCallum Cancer Centre
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
PHASE2Ameloblastoma is the most common benign odontogenic tumor, characterized by...
Location
Multiple Locations
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
PHASE2This phase 2 trial will investigate the efficacy and safety of trametinib a...
Location
Universitair Ziekenhuis Brussel
A Clinical Trial of Patients With Melanoma
PHASE1This study is being done to find out if the combination of dabrafenib, tram...
Location
University of Texas Southwestern Medical Center
Melanoma Metastasized to the Brain and Steroids
PHASE2This clinical trial is to clarify whether treatment with a checkpoint inhib...
Location
Herlev Universityhospital
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
PHASE1This research study is studying a combination of targeted therapies as a po...
Location
Dana Farber Cancer Institute
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
PHASE2This is a global, multi-centre, open-label, study of GSK2118436 conducted i...
Location
GSK Investigational Site
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
PHASE1Present clinical study will be conducted in China to evaluate the pharmacok...
Location
Multiple Locations
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
PHASE3The purpose of this study was to evaluate safety and efficacy of the combin...
Location
California Cancer Associates for Research and Excellence
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
PHASE2This was a Phase II, open-label, non-randomized, multi-center study of oral...
Location
Novartis Investigative Site